Genedrive PLC High clinical accuracy in India study

TIDMGDR

Genedrive PLC

20 November 2020

genedrive plc

("genedrive" or the "Company")

Genedrive HCV ID Kit demonstrates high clinical accuracy in India study

Hepatitis C virus testing kit reveals 100% sensitivity and specificity when compared to Abbott Real time HCV test

Genedrive plc (AIM:GDR), the near patient molecular diagnostics company, announces the publication of the study data for the 'Evaluation of the Point of Care Molecular Diagnostic Genedrive HCV ID Kit for the detection of HCV RNA in clinical samples'.

The study(1) was led by Dr Ekta Gupta at ILBS, New Delhi, India. The objective of the study was to determine the diagnostic accuracy of the Genedrive HCV ID Kit, as a confirmatory test for seropositive hepatitis C virus (HCV) patients in Indian demographic settings.

Details of the study are published online here: https://tinyurl.com/y2pfylwo

The diagnostic accuracy of the Genedrive HCV ID Kit was evaluated by comparing the test with the Abbott Real time HCV test on the lab-based Abbott m2000 platform in an Indian demographic and across a range of different genotypes, to ensure suitability for introduction of the product to the Indian population. In India the circulation of HCV genotype is predominantly genotypes 3 and 1 with live infections of HCV estimated at between 6-12 million(2) .

150 HCV RNA positive and 170 HCV RNA negative samples were tested using both methods. The comparison revealed 100% sensitivity (95% CI 97.9 - 100%) and 100% specificity (95% CI 97.9 - 100%). The overall diagnostic accuracy was 100% (95% CI 98.9 - 100%).

Overall, the study demonstrates that the Genedrive HCV ID Kit is suitable for use in India and can be used for decentralised testing of HCV thereby reducing the loss of patients to follow up.

David Budd, CEO of genedrive plc, said: "These excellent clinical results for our HCV assay further validate the applicability of the test for a decentralised setting. India is a key target market for our assay and we are excited about the commercial prospects in the region."

1 Unique publication reference: DOI 10.1017/S0950268820002812.

2 Ministry of Health and Family Welfare Government of India, 2019, https://tinyurl.com/y3box279

For further details please contact:

 
 genedrive plc                                                                 +44 (0)161 989 0245 
 David Budd: CEO / Matthew Fowler: 
  CFO 
 
 Peel Hunt LLP (Nominated Adviser 
  and Joint Broker)                                                            +44 (0)20 7418 8900 
 James Steel / Oliver Jackson 
 
            finnCap (Joint Broker)                                             +44 (0)20 7220 0500 
            Geoff Nash / Kate Bannatyne / Alice 
             Lane 
 
 Walbrook PR Ltd (Media & Investor                 +44 (0)20 7933 8780 or genedrive@walbrookpr.com 
  Relations) 
                                                                 +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                                741 001

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive(R) Point of Care version of the assay, both based on Genedrive(R) chemistry.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABLBFTMTABBRM

(END) Dow Jones Newswires

November 20, 2020 02:00 ET (07:00 GMT)

Epistem (LSE:EHP)
Historical Stock Chart
From Dec 2024 to Jan 2025